Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RVU120 |
Synonyms | |
Therapy Description |
RVU120 (SEL120) selectively inhibits CDK8, resulting in decreased STAT5 and STAT1 phosphorylation and downstream signaling, and potentially leading to reduced tumor cell growth (PMID: 28422713). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RVU120 | SEL120|SEL 120-34|SEL120-34A|RVU 120|RVU-120 | CDK8 Inhibitor 5 | RVU120 (SEL120) selectively inhibits CDK8, resulting in decreased STAT5 and STAT1 phosphorylation and downstream signaling, and potentially leading to reduced tumor cell growth (PMID: 28422713). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04021368 | Phase I | RVU120 | SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | POL | 0 |
NCT06268574 | Phase II | RVU120 | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52) | Recruiting | POL | ITA | FRA | ESP | CAN | 0 |
NCT05052255 | Phase Ib/II | RVU120 | RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | Active, not recruiting | POL | ESP | 0 |